Outcome of Patients with Relapsed or Refractory Nonrhabdomyosarcoma Soft Tissue Sarcomas Enrolled in Phase 2 Cooperative Group Clinical Trials: A Report from the Children's Oncology Group

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2024 Mar 12

PMID 38470405

Authors

Sapna Oberoi

Amira Qumseya

Wei Xue

Rajkumar Venkatramani

Aaron R Weiss

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to estimate the event-free survival (EFS) of children and young adults with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) treated in nonrandomized phase 2 studies conducted by the Children's Oncology Group (COG) and predecessor groups to establish a benchmark EFS for future phase 2 NRSTS trials evaluating the activity of novel agents.

Methods: A retrospective analysis of patients with recurrent or refractory NRSTS prospectively enrolled in nonrandomized phase 2 COG and predecessor group trials between 1994 and 2015 was conducted. EFS was defined as disease progression/relapse or death and calculated via the Kaplan-Meier method. The log-rank test and relative risk regression were used to compare EFS distribution by age at enrollment, sex, race, NRSTS histology, prior lines of therapy, calendar year of trial, and type of radiographic response.

Results: In total, 137 patients were enrolled in 13 phase 2 trials. All trials used radiographic response rate as a primary outcome, and none of the agents used were considered active on the basis of trial-specified thresholds. The estimated median EFS and 6-month EFS of the entire study cohort was 1.5 months (95% confidence interval [CI], 1.3-1.8 months) and 19.4% (95% CI, 12.7%-26%), respectively. No difference in EFS was observed by age at enrollment, sex, race, NRSTS histology subtype, prior lines of therapies, and trial initiation year. EFS significantly differed by radiographic response.

Conclusions: The EFS for children and young adults with relapsed or refractory NRSTS remains suboptimal. Established EFS can be referenced as a benchmark for future single-agent phase 2 trials incorporating potentially active novel agents in this population.

References

Mosse Y, Fox E, Teachey D, Reid J, Safgren S, Carol H . A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019; 25(11):3229-3238. PMC: 6897379. DOI: 10.1158/1078-0432.CCR-18-2675. View

Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L . Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010; 16(2):750-4. PMC: 3086796. DOI: 10.1158/1078-0432.CCR-09-1906. View

Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J . Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023; 41(31):4842-4848. PMC: 10852395. DOI: 10.1200/JCO.23.00045. View

Schmoll H, Lindner L, Reichardt P, Heissner K, Kopp H, Kessler T . Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 7(2):255-262. PMC: 7758834. DOI: 10.1001/jamaoncol.2020.6564. View

Van Glabbeke M, Verweij J, Judson I, Nielsen O . Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002; 38(4):543-9. DOI: 10.1016/s0959-8049(01)00398-7. View

Tanaka K, Kawano M, Iwasaki T, Itonaga I, Tsumura H . Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation. BMC Cancer. 2019; 19(1):56. PMC: 6330427. DOI: 10.1186/s12885-019-5268-2. View

Chiaravalli S, Bergamaschi L, Livellara V, Sironi G, Puma N, Nigro O . Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse. Eur J Cancer. 2022; 169:179-187. DOI: 10.1016/j.ejca.2022.03.037. View

van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

Bomgaars L, Bernstein M, Krailo M, Kadota R, Das S, Chen Z . Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007; 25(29):4622-7. DOI: 10.1200/JCO.2007.11.6103. View

10.

Schoffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E . Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028):1629-37. DOI: 10.1016/S0140-6736(15)01283-0. View

11.

Langevin A, Bernstein M, Kuhn J, Blaney S, Ivy P, Sun J . A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2007; 50(3):577-80. DOI: 10.1002/pbc.21274. View

12.

Baruchel S, Pappo A, Krailo M, Baker K, Wu B, Villaluna D . A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2011; 48(4):579-85. DOI: 10.1016/j.ejca.2011.09.027. View

13.

Beaty 3rd O, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R . A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010; 55(3):440-5. PMC: 4665115. DOI: 10.1002/pbc.22544. View

14.

Ferrari A, Sultan I, Huang T, Rodriguez-Galindo C, Shehadeh A, Meazza C . Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011; 57(6):943-9. PMC: 4261144. DOI: 10.1002/pbc.23252. View

15.

Parsons D, Janeway K, Patton D, Winter C, Coffey B, Williams P . Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022; 40(20):2224-2234. PMC: 9273376. DOI: 10.1200/JCO.21.02838. View

16.

Spunt S, Million L, Chi Y, Anderson J, Tian J, Hibbitts E . A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2019; 21(1):145-161. PMC: 6946838. DOI: 10.1016/S1470-2045(19)30672-2. View

17.

Zer A, Prince R, Amir E, Abdul Razak A . Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. J Clin Oncol. 2016; 34(13):1469-75. DOI: 10.1200/JCO.2015.64.3437. View

18.

Bond M, Bernstein M, Pappo A, Schultz K, Krailo M, Blaney S . A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2007; 50(2):254-8. DOI: 10.1002/pbc.21132. View

19.

Collier 3rd A, Krailo M, Dang H, Dubois S, Hawkins D, Bernstein M . Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021; 68(12):e29333. PMC: 8541905. DOI: 10.1002/pbc.29333. View

20.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay J, Bertucci F . Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016; 17(12):1732-1742. DOI: 10.1016/S1470-2045(16)30507-1. View